Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $1.40 in the prior trading day, Macrogenics Inc (NASDAQ: MGNX) closed at $1.36, down -2.86%. In other words, the price has decreased by -$2.86 from its previous closing price. On the day, 0.53 million shares were traded.
Ratios:
Our goal is to gain a better understanding of MGNX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.11 and its Current Ratio is at 3.28. In the meantime, Its Debt-to-Equity ratio is 0.47 whereas as Long-Term Debt/Eq ratio is at 0.41.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 15 ’25 when Smith Beth Ann sold 423 shares for $2.56 per share. The transaction valued at 1,083 led to the insider holds 9,532 shares of the business.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.56 while its Price-to-Book (P/B) ratio in mrq is 1.08.
Stock Price History:
Over the past 52 weeks, MGNX has reached a high of $5.77, while it has fallen to a 52-week low of $0.99. The 50-Day Moving Average of the stock is -8.50%, while the 200-Day Moving Average is calculated to be -51.69%.
Shares Statistics:
A total of 63.09M shares are outstanding, with a floating share count of 57.94M. Insiders hold about 8.16% of the company’s shares, while institutions hold 80.39% stake in the company.
Earnings Estimates
Macrogenics Inc (MGNX) is presently subject to a detailed evaluation by 1.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.35, with high estimates of -$0.35 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$1.82 and -$1.82 for the fiscal current year, implying an average EPS of -$1.82. EPS for the following year is -$2.86, with 1.0 analysts recommending between -$2.86 and -$2.86.
Revenue Estimates
6 analysts predict $16.74M in revenue for the current quarter. It ranges from a high estimate of $36M to a low estimate of $7.5M. As of the current estimate, Macrogenics Inc’s year-ago sales were $10.8MFor the next quarter, 6 analysts are estimating revenue of $23.76M. There is a high estimate of $48.57M for the next quarter, whereas the lowest estimate is $7.5M.
A total of 6 analysts have provided revenue estimates for MGNX’s current fiscal year. The highest revenue estimate was $149.8M, while the lowest revenue estimate was $30M, resulting in an average revenue estimate of $81.38M. In the same quarter a year ago, actual revenue was $149.96MBased on 5 analysts’ estimates, the company’s revenue will be $96.55M in the next fiscal year. The high estimate is $228.75M and the low estimate is $30M.
